Qualitative Evaluation of Tear Fluid and Blood for Auto Antibodies Produced in Response to COVID-19
Completed
- Conditions
- SARS-CoV 2 InfectionCovid19
- Interventions
- Diagnostic Test: SARS-CoV2 Autoantibody detection
- Registration Number
- NCT04542980
- Lead Sponsor
- Namida Lab
- Brief Summary
This study objective is to collect tear and blood samples from individuals with positive SARS-COV2 diagnosis and test those samples for the presence of various SARS-COV2 viral antigens and autoantibodies.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 44
Inclusion Criteria
- 18 years of age or older Has been tested for SARS-CoV2 and awaiting results Sample collection for SARS-CoV2 testing Tested positive for SARS-CoV2 virus (confirmed by RT-PCR) prior to enrollment
Exclusion Criteria
- Under 18 years of age Concurrent eye infection or trauma unrelated to presence of SARS-CoV2 virus. Advanced COVID-19 state what would preclude safe and feasible sample collection.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description SARS-CoV2 Positive SARS-CoV2 Autoantibody detection Tear Samples: Tear samples will be collected from 100 patients who have tested positive for the SARS-CoV2 virus. A total of 100 Blood samples will be drawn using standard phlebotomy techniques for venipuncture from patients who have tested positive for the SARS-CoV2 virus.
- Primary Outcome Measures
Name Time Method Qualitative assessment of IgM and/or IgG by indirect ELISA assay. through study completion, up to 8 months Determination of the presence or absence of IgM and/or IgG autoantibodies in response to SARS-CoV2 infection. In the case of presence, concentration may be determined as well.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Namida Lab
🇺🇸Fayetteville, Arkansas, United States